You are here: Industry Insights > Soliris

News List

AZ scores final clearance for Alexion acquisition in the UK pharmatimes
July 15, 2021
AstraZeneca (AZ) is expecting its acquisition of Alexion Pharmaceuticals to close on 21 July after receiving final clearance from the UK Competition and Markets Authority (CMA).
SMC endorses Alexion’s Ultomiris pharmatimes
May 12, 2021
The Scottish Medicines Consortium (SMC) has accepted a treatment for an ultra-rare disease that can cause progressive injury to vital organs via damage to the walls of blood vessels and blood clots in its May decisions.
Soliris (Eculizumab) Injection Approved to Treat Neuromyelitis Optica Spectrum Disorder drugs
July 01, 2019
Soliris (Eculizumab) Injection Approved to Treat Neuromyelitis Optica Spectrum Disorder.
FDA approves first treatment for neuromyelitis optica spectrum disorder, a rare autoimmune disease of the central nervous system worldpharmanews
July 01, 2019
FDA approves first treatment for neuromyelitis optica spectrum disorder, a rare autoimmune disease of the central nervous system.
Alexion Receives FDA Approval of Soliris (eculizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder drugs
June 28, 2019
Alexion Receives FDA Approval of Soliris (eculizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder.
Alexion aims for fourth rare disease use for blockbuster Soliris pharmaphorum
February 27, 2019
The FDA has granted a fast review for Alexion Pharmaceuticals’ filing for its Soliris, as a treatment for a rare neurological disease that leads to worsening disability, blindness, paralysis, and possibly early death.
Alexion runs toward big Ultomiris goals with early Soliris switching success fiercepharma
February 24, 2019
Alexion has big goals for Soliris follow-up Ultomiris in paroxysmal nocturnal hemoglobinuria (PNH), and wooing patients over from predecessor Soliris is key. But so far, executives say, those aims are right on track.
Ra Pharma files $100M round as Soliris rival clears phase 2 trial fiercebiotech
December 27, 2018
Armed with a phase 2 win for its lead drug zilucoplan in rare disease myasthenia gravis (MG), Ra Pharma has pressed the button on a public funding round that it hopes could raise up to $115 million......
Alexion eyes $500M-plus in new Soliris sales with latest rare-disease win fiercepharma
September 25, 2018
Alexion has already seen major success expanding flagship Soliris into multiple indications. And it may just have another nod on the horizon.
Alexion bags Japanese approval for Soliris biospectrumasia
January 04, 2018
Soliris is the first and only approved Complement Inhibitor in Japan as a Treatment for Patients with Myasthenia gravis, a Chronic and Debilitating Neuromuscular Disorder

Previous page 1 2 Next page